Editorials
Lessons from the withdrawal of rofecoxib
BMJ 2004; 329 doi: https://doi.org/10.1136/bmj.329.7471.867 (Published 14 October 2004) Cite this as: BMJ 2004;329:867
Data supplement
Additional references
w1. Jüni P, Dieppe P, Egger M. Risk of myocardial infarction associated with selective COX-2 inhibitors: questions remain. Arch Intern Med 2002;162:2639-40.
w2. Dalen JE. Selective COX-2 inhibitors, NSAIDs, aspirin, and myocardial infarction. Arch Intern Med 2002;162:1091-2.
Related articles
- Letter Published: 27 January 2005; BMJ 330 doi:10.1136/bmj.330.7485.255-c
- Letter Published: 02 December 2004; BMJ 329 doi:10.1136/bmj.329.7478.1342
- Letter Published: 02 December 2004; BMJ 329 doi:10.1136/bmj.329.7478.1342-a
- Editorial Published: 09 June 2005; BMJ 330 doi:10.1136/bmj.330.7504.1342
See more
- Chemoprevention of colorectal cancer in individuals with previous colorectal neoplasia: systematic review and network meta-analysisBMJ December 05, 2016, 355 i6188; DOI: https://doi.org/10.1136/bmj.i6188
- Proton pump inhibitors and community acquired pneumoniaBMJ November 17, 2016, 355 i6041; DOI: https://doi.org/10.1136/bmj.i6041
- NSAIDs and the failing heartBMJ September 28, 2016, 354 i5163; DOI: https://doi.org/10.1136/bmj.i5163
- Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control studyBMJ September 28, 2016, 354 i4857; DOI: https://doi.org/10.1136/bmj.i4857
- Data feedback and behavioural change intervention to improve primary care prescribing safety (EFIPPS): multicentre, three arm, cluster randomised controlled trialBMJ August 18, 2016, 354 i4079; DOI: https://doi.org/10.1136/bmj.i4079
Cited by...
- Novel oral anticoagulants: too good to be true?
- Safety of new medicines in young children
- The use of medication and nutritional supplements during FIFA World Cups 2002 and 2006
- COX 2 inhibitors, traditional NSAIDs, and the heart
- Pills, thrills, and bellyaches
- Sentinel systems are needed for long term adverse drug reactions
- Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials
- Hit parade
- Lessons from the withdrawal of rofecoxib: France has policy for overall assessment of public health impact of new drugs
- Lessons from the withdrawal of rofecoxib: Observational studies should not be forgotten